Laird Norton Wetherby Wealth Management LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 77,245 shares of the company's stock after selling 5,989 shares during the period. Johnson & Johnson makes up about 0.5% of Laird Norton Wetherby Wealth Management LLC's investment portfolio, making the stock its 26th biggest position. Laird Norton Wetherby Wealth Management LLC's holdings in Johnson & Johnson were worth $11,171,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of JNJ. Czech National Bank increased its position in shares of Johnson & Johnson by 6.5% during the fourth quarter. Czech National Bank now owns 522,021 shares of the company's stock worth $75,495,000 after acquiring an additional 31,640 shares in the last quarter. Aprio Wealth Management LLC grew its position in Johnson & Johnson by 2.9% in the fourth quarter. Aprio Wealth Management LLC now owns 8,055 shares of the company's stock valued at $1,165,000 after purchasing an additional 225 shares in the last quarter. Clark & Stuart Inc bought a new position in Johnson & Johnson in the fourth quarter valued at $7,647,000. Crescent Sterling Ltd. grew its position in Johnson & Johnson by 0.3% in the fourth quarter. Crescent Sterling Ltd. now owns 23,239 shares of the company's stock valued at $3,361,000 after purchasing an additional 72 shares in the last quarter. Finally, Fiduciary Alliance LLC grew its position in Johnson & Johnson by 7.1% in the fourth quarter. Fiduciary Alliance LLC now owns 78,738 shares of the company's stock valued at $11,387,000 after purchasing an additional 5,245 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Johnson & Johnson
In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Price Performance
JNJ stock traded down $5.43 during mid-day trading on Tuesday, hitting $148.71. The stock had a trading volume of 10,438,425 shares, compared to its average volume of 7,924,410. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market capitalization of $357.81 billion, a P/E ratio of 22.36, a P/E/G ratio of 2.56 and a beta of 0.42. The firm has a fifty day simple moving average of $157.33 and a 200 day simple moving average of $154.14.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.50%. Johnson & Johnson's payout ratio is 57.84%.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $169.00 to $153.00 in a research report on Tuesday. Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Bank of America decreased their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $170.88.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
